85,586,795 Todos shares owned by AMARANTUS , addit
Post# of 30067
(Total Views: 565)
Posted On: 07/30/2020 12:50:24 PM
85,586,795 Todos shares owned by AMARANTUS , addition a 10% royalty on LymPro intellectual property.
Daniel Hirsch, Chief Financial Officer of Todos. “With this asset now fully in our portfolio, and with the expected cash flow from our COVID-19 testing business, we believe we can continue to increase the value of LymPro as we bring it to market through our emerging U.S. and international sales channels. Additionally, because we are seeing a number of complications after recovery from COVID-19, we believe it is prudent to begin monitoring patients for early warning signs of disease, including Alzheimer’s and cancer. If early pathology emerges, it will potentially be more treatable than if found later in the course of disease.”
https://investor.todosmedical.com/news-events...eakthrough
As far as LymPro moving into a CLIA Lab, Gerald talks about moving it into a Lab they are in the process of purchasing/acquiring.
To be able to validate LymPro essentially for free and then run testing all in house will be one, an inexpensive fast track to market and then two, a steady revenue stream once companies begin using LymPro. Dual revenue streams.
1. For LymPro
2. For running the study samples through the CLIA lab.
https://investorshangout.com/post/view?id=575...zz6ThBwOqI
Todos Medical Appoints Dr. Lauren Chung to its Board of Directors
“We have been working with Dr. Chung for some time on an informal basis, and she has provided significant insight and guidance on positioning the Company for future growth,” said Gerald E. Commissiong, President & CEO of Todos Medical ( TOMDF Loading...). “We believe Alzheimer’s disease is effectively cancer of post-mitotic neurons, and this is the basis for aligning Todos’ cancer platform with the LymPro Alzheimer’s platform. Given Dr. Chung’s extensive background in the scientific and business communities in the Alzheimer’s space, and broad reach into the Asian capital markets, now is the time to bring Lauren on board as we build the Company’s profile as a leader in immune-based diagnostics for cancer, Alzheimer’s disease and COVID-19 in preparation for national stock exchange listing.”
https://investorshangout.com/post/view?id=573...z6ThEHDj5N
Dr. Chung serves on the business review board of Alzheimer’s Drug Discovery Foundation
https://todosmedical.com/about-us/board-of-advisors/
The mission of the Alzheimer's Drug Discovery Foundation is to rapidly accelerate the discovery of drugs to prevent, treat and cure Alzheimer's disease.
OUR STRATEGY
The ADDF focuses on translating the knowledge we have gained about the causes of Alzheimer's disease into drugs to conquer it. We support an underfunded area—preclinical drug discovery and early-stage clinical trials of potential drug targets—that is often called the "valley of death" because it's where good ideas go to die. These projects hold great promise, but also great risk. And most are not far enough along in the drug development pipeline to attract financial support from the pharmaceutical industry, federal funders, or other major partners. By assuming the risk and bridging this critical gap in funding, the ADDF enables leading scientists to pursue pioneering ideas to cure Alzheimer's disease that would otherwise go unexplored.
https://www.alzdiscovery.org/about-addf
Aloha
Daniel Hirsch, Chief Financial Officer of Todos. “With this asset now fully in our portfolio, and with the expected cash flow from our COVID-19 testing business, we believe we can continue to increase the value of LymPro as we bring it to market through our emerging U.S. and international sales channels. Additionally, because we are seeing a number of complications after recovery from COVID-19, we believe it is prudent to begin monitoring patients for early warning signs of disease, including Alzheimer’s and cancer. If early pathology emerges, it will potentially be more treatable than if found later in the course of disease.”
https://investor.todosmedical.com/news-events...eakthrough
As far as LymPro moving into a CLIA Lab, Gerald talks about moving it into a Lab they are in the process of purchasing/acquiring.
To be able to validate LymPro essentially for free and then run testing all in house will be one, an inexpensive fast track to market and then two, a steady revenue stream once companies begin using LymPro. Dual revenue streams.
1. For LymPro
2. For running the study samples through the CLIA lab.
https://investorshangout.com/post/view?id=575...zz6ThBwOqI
Todos Medical Appoints Dr. Lauren Chung to its Board of Directors
“We have been working with Dr. Chung for some time on an informal basis, and she has provided significant insight and guidance on positioning the Company for future growth,” said Gerald E. Commissiong, President & CEO of Todos Medical ( TOMDF Loading...). “We believe Alzheimer’s disease is effectively cancer of post-mitotic neurons, and this is the basis for aligning Todos’ cancer platform with the LymPro Alzheimer’s platform. Given Dr. Chung’s extensive background in the scientific and business communities in the Alzheimer’s space, and broad reach into the Asian capital markets, now is the time to bring Lauren on board as we build the Company’s profile as a leader in immune-based diagnostics for cancer, Alzheimer’s disease and COVID-19 in preparation for national stock exchange listing.”
https://investorshangout.com/post/view?id=573...z6ThEHDj5N
Dr. Chung serves on the business review board of Alzheimer’s Drug Discovery Foundation
https://todosmedical.com/about-us/board-of-advisors/
The mission of the Alzheimer's Drug Discovery Foundation is to rapidly accelerate the discovery of drugs to prevent, treat and cure Alzheimer's disease.
OUR STRATEGY
The ADDF focuses on translating the knowledge we have gained about the causes of Alzheimer's disease into drugs to conquer it. We support an underfunded area—preclinical drug discovery and early-stage clinical trials of potential drug targets—that is often called the "valley of death" because it's where good ideas go to die. These projects hold great promise, but also great risk. And most are not far enough along in the drug development pipeline to attract financial support from the pharmaceutical industry, federal funders, or other major partners. By assuming the risk and bridging this critical gap in funding, the ADDF enables leading scientists to pursue pioneering ideas to cure Alzheimer's disease that would otherwise go unexplored.
https://www.alzdiscovery.org/about-addf
Aloha
(1)
(0)